Natalie Collins MD PhD
Assistant Professor in Pediatrics, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School
Join to view full profile
450 Brookline AveBoston, MA 02215
Phone+1 617-632-3270
Dr. Collins is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Natalie Collins is a pediatric hematology and oncology specialist based in Boston, MA. She completed her fellowship and residency at Boston Children’s Hospital/Boston Medical Center, following her medical education at the University of Virginia School of Medicine. Since 2015, she has been an instructor in pediatrics at the Dana-Farber Cancer Institute. Dr. Collins has authored multiple publications in high-impact journals, including on topics like the feasibility of atezolizumab in pediatric oncology and the use of cell-free DNA for early tumor detection. She is also involved in clinical trials, notably researching GVAX plus checkpoint blockade in neuroblastoma.
Education & Training
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 2011 - 2015- Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 2009 - 2011
University of Virginia School of MedicineClass of 2009
Certifications & Licensure
MA State Medical License 2011 - 2027
NH State Medical License 2024 - 2024
OR State Medical License 2021 - 2022
ME State Medical License 2021 - 2021
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- GVAX Plus Checkpoint Blockade in Neuroblastoma Start of enrollment: 2020 Jan 29
Publications & Presentations
PubMed
- Omitting Bone Marrow Sampling in FDG-Avid Rhabdomyosarcoma With 2-[F]FDG PET-Negative Marrow: Results From an International Retrospective Study.Federico Mercolini, Marissa Just, Barry L Shulkin, Natalie B Collins, Jacquelyn Crane
Journal of Clinical Oncology. 2026-08-24 - 1 citationsSARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST).AeRang Kim, Karla V Ballman, Pamela L Wolters, Rachel S Heise, Jack F Shern
Clinical Cancer Research. 2026-03-16 - Children and Young People With First Relapse or Progression of Upfront Metastatic Rhabdomyosarcoma: An Analysis of Clinical Features and Outcomes From the INternationa...Ajla T Wasti, Gianni Bisogno, Beatrice Coppadoro, Ilaria Zanetti, Martin Ebinger
Cancer Medicine. 2026-03-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
